PHILADELPHIA, Nov. 22,
2023 /PRNewswire/ -- Carisma Therapeutics Inc.
(Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage
biopharmaceutical company focused on discovering and developing
innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive
Officer, will participate in a fireside chat at the 6th
Annual Evercore ISI HealthCONx Conference on Wednesday, November 29 at 2:35 pm ET.
An audio webcast of the event will be available on the Company's
Investor Events section of the Investor Relations webpage and will
be archived for a limited time following the event.
About Carisma
Carisma Therapeutics Inc. is a clinical stage biopharmaceutical
company focused on utilizing our proprietary macrophage and
monocyte cell engineering platform to develop transformative
immunotherapies to treat cancer and other serious diseases. We have
created a comprehensive, differentiated proprietary cell therapy
platform focused on engineered macrophages and monocytes, cells
that play a crucial role in both the innate and adaptive immune
response. Carisma is headquartered in Philadelphia, PA. For more information, please
visit www.carismatx.com.
Cautionary Note on Forward-Looking Statements
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
"forward-looking statements" within the meaning of The Private
Securities Litigation Reform Act of 1995. These statements include,
but are not limited to, statements relating to Carisma's business,
strategy, future operations, cash runway, the advancement of
Carisma's product candidates and product pipeline, and clinical
development of Carisma's product candidates, including expectations
regarding timing of initiation and results of clinical trials. The
words "anticipate," "believe," "contemplate," "continue," "could,"
"estimate," "expect," "goals," "intend," "may," "might," "outlook,"
"plan," "project," "potential," "predict," "target," "possible,"
"will," "would," "could," "should," and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Any forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in, or implied by,
such forward-looking statements. For a discussion of these risks
and uncertainties, and other important factors, any of which could
cause Carisma's actual results to differ from those contained in
the forward-looking statements, see the "Risk Factors" set forth in
the Company's Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on November 9, 2023, as well as discussions of
potential risks, uncertainties, and other important factors in
Carisma's other recent filings with the Securities and Exchange
Commission. Any forward-looking statements that are made in this
press release speak as of the date of this press release. Carisma
undertakes no obligation to revise the forward-looking statements
or to update them to reflect events or circumstances occurring
after the date of this press release, whether as a result of new
information, future developments or otherwise, except as required
by the federal securities laws.
Media Contact:
Julia
Stern
(763) 350-5223
jstern@realchemistry.com
Investor Contact:
investors@carismatx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-participate-in-evercore-isi-healthconx-conference-301995316.html
SOURCE Carisma Therapeutics Inc.